122 related articles for article (PubMed ID: 12170772)
1. Phase I study of perillyl alcohol in patients with refractory malignancies.
Murren JR; Pizzorno G; DiStasio SA; McKeon A; Peccerillo K; Gollerkari A; McMurray W; Burtness BA; Rutherford T; Li X; Ho PT; Sartorelli A
Cancer Biol Ther; 2002; 1(2):130-5. PubMed ID: 12170772
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Ripple GH; Gould MN; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Binger K; Tutsch KD; Pomplun M; Wahamaki A; Marnocha R; Wilding G; Bailey HH
Clin Cancer Res; 2000 Feb; 6(2):390-6. PubMed ID: 10690515
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of perillyl alcohol administered daily.
Ripple GH; Gould MN; Stewart JA; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Pomplun M; Wilding G; Bailey HH
Clin Cancer Res; 1998 May; 4(5):1159-64. PubMed ID: 9607573
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Azzoli CG; Miller VA; Ng KK; Krug LM; Spriggs DR; Tong WP; Riedel ER; Kris MG
Cancer Chemother Pharmacol; 2003 Jun; 51(6):493-8. PubMed ID: 12695855
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC
Cancer Chemother Pharmacol; 1998; 42(2):111-7. PubMed ID: 9654110
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.
Bailey HH; Levy D; Harris LS; Schink JC; Foss F; Beatty P; Wadler S
Gynecol Oncol; 2002 Jun; 85(3):464-8. PubMed ID: 12051875
[TBL] [Abstract][Full Text] [Related]
10. Perillyl alcohol: applications in oncology.
Belanger JT
Altern Med Rev; 1998 Dec; 3(6):448-57. PubMed ID: 9855569
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol.
Stark MJ; Burke YD; McKinzie JH; Ayoubi AS; Crowell PL
Cancer Lett; 1995 Sep; 96(1):15-21. PubMed ID: 7553603
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
Phillips LR; Malspeis L; Supko JG
Drug Metab Dispos; 1995 Jul; 23(7):676-80. PubMed ID: 7587953
[TBL] [Abstract][Full Text] [Related]
13. Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer.
Crowell PL; Siar Ayoubi A; Burke YD
Adv Exp Med Biol; 1996; 401():131-6. PubMed ID: 8886131
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.
Liu G; Oettel K; Bailey H; Ummersen LV; Tutsch K; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Rezazadeh H; McGovern J; Robinson E; DeMets D; Wilding G
Invest New Drugs; 2003 Aug; 21(3):367-72. PubMed ID: 14578686
[TBL] [Abstract][Full Text] [Related]
15. Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma.
Zhang Z; Chen H; Chan KK; Budd T; Ganapathi R
J Chromatogr B Biomed Sci Appl; 1999 May; 728(1):85-95. PubMed ID: 10379660
[TBL] [Abstract][Full Text] [Related]
16. R-Limonene metabolism in humans and metabolite kinetics after oral administration.
Schmidt L; Göen T
Arch Toxicol; 2017 Mar; 91(3):1175-1185. PubMed ID: 27325307
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content.
Chow HH; Salazar D; Hakim IA
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1472-6. PubMed ID: 12433729
[TBL] [Abstract][Full Text] [Related]
18. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene.
Haag JD; Gould MN
Cancer Chemother Pharmacol; 1994; 34(6):477-83. PubMed ID: 7923558
[TBL] [Abstract][Full Text] [Related]
19. Analysis of perillic acid in plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Ikechukwu Ezennia E; Phillips LR; Wolfe TL; Esmail Tabibi S
J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):354-8. PubMed ID: 9061476
[TBL] [Abstract][Full Text] [Related]
20. Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth.
Crowell PL; Lin S; Vedejs E; Gould MN
Cancer Chemother Pharmacol; 1992; 31(3):205-12. PubMed ID: 1464157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
